For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Opdivo Tops Japan Sales Ranking in February: Encise
March 10, 2022
- Astellas to Submit Improvement Plans for Gene Therapy Trial by September over Patient Deaths
March 10, 2022
- Double-Digit Slashes to Hit 44 Major Drugs in 2022 Price Revision: Top 5 Product Poll
March 9, 2022
- Rakuten Medical’s Photoimmunotherapy Platform Renamed Alluminox
March 9, 2022
- Nobelpharma, Toyo Ink Tie Up on Biologics Development, Overseas Expansion
March 9, 2022
- Nippon Chemiphar Gets Japan Sales Rights to Another Delta-Fly Cancer Med
March 9, 2022
- Astellas’s Hot Flash Drug Fezolinetant Delivers Positive PIII Data
March 8, 2022
- SanBio’s Sakigake Cell Therapy Finally Filed in Japan for Traumatic Brain Injury
March 8, 2022
- Gazyva-Calquence Combo Filed in Japan for CLL: Chugai/AstraZeneca
March 8, 2022
- Japan Ethical Drug Sales Up 5.8% in January: Crecon
March 8, 2022
- Oncolys, NIID Team Up to Unlock Oral COVID-19 Med’s Mechanism of Action
March 8, 2022
- Big 3 Japan Generic Makers See Average 8.2% Price Cut in FY2022: Jiho Poll
March 7, 2022
- Shionogi’s COVID-19 Jab Non-Inferior to Pfizer Shot in Japan Booster Trial
March 7, 2022
- Eisai Suffers 9%-Plus Cut, Sumitomo Dainippon Over 8% in 2022 Drug Price Revision: Jiho Poll
March 7, 2022
- Eisai Begins Data Submission for Lecanemab for Swift Approval in Japan
March 7, 2022
- AZ Japan Working towards 100% Electric Vehicle Fleet by 2025, but Challenges Remain
March 3, 2022
- Sumitomo Dainippon to Succeed Fabrazyme Biosimilar Sales from JCR
March 2, 2022
- Trulicity, Rybelsus Might Gain Ground in GLP-1 Market amid Ozempic Supply Woes
March 2, 2022
- Astellas Returns Rights for Pneumococcal Vaccine to Affinivax on Strategic Prioritization
March 2, 2022
- Sanwa Kagaku Bags Japan Rights to Crinetics’ Paltusotine
March 2, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…